Jörgen Carlsson

Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology

Acker, Till; Fandrey, Joachim; Carlsson, Jörgen

Part of Pflügers Archiv, p. 1227-1229, 2025

• DOI for Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology
• Download full text (pdf) of Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology

Analysis of radiation effects in two irradiated tumor spheroid models

Al-Ramadan, Afkar; Mortensen, Anja; Carlsson, Jörgen; Nestor, Marika V.

Part of Oncology Letters, p. 3008-3016, 2018

• DOI for Analysis of radiation effects in two irradiated tumor spheroid models

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Sandberg, Dan T; Tolmachev, Vladimir; Velikyan, Irina; Olofsson, Helena et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1337-1346, 2017

• DOI for Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
• Download full text (pdf) of Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Sörensen, Jens; Velikyan, Irina; Sandberg, Dan; Wennborg, Anders et al.

Part of Theranostics, p. 262-271, 2016

• DOI for Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
• Download full text (pdf) of Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Good manufacturing practice production of [⁶⁸Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Velikyan, Irina; Wennborg, Anders; Feldwisch, Joachim; Lindman, Henrik et al.

Part of American Journal of Nuclear Medicine and Molecular Imaging, p. 135-153, 2016

Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology

Acker, Till; Fandrey, Joachim; Carlsson, Jörgen

Part of Pflügers Archiv, p. 1227-1229, 2025

• DOI for Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology
• Download full text (pdf) of Professor Helmut Acker (1939-2025): A Pioneer in Oxygen Sensing and Molecular Physiology

Analysis of radiation effects in two irradiated tumor spheroid models

Al-Ramadan, Afkar; Mortensen, Anja; Carlsson, Jörgen; Nestor, Marika V.

Part of Oncology Letters, p. 3008-3016, 2018

• DOI for Analysis of radiation effects in two irradiated tumor spheroid models

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Sandberg, Dan T; Tolmachev, Vladimir; Velikyan, Irina; Olofsson, Helena et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1337-1346, 2017

• DOI for Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.
• Download full text (pdf) of Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT.

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Sörensen, Jens; Velikyan, Irina; Sandberg, Dan; Wennborg, Anders et al.

Part of Theranostics, p. 262-271, 2016

• DOI for Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
• Download full text (pdf) of Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT

Good manufacturing practice production of [⁶⁸Ga]Ga-ABY-025 for HER2 specific breast cancer imaging.

Velikyan, Irina; Wennborg, Anders; Feldwisch, Joachim; Lindman, Henrik et al.

Part of American Journal of Nuclear Medicine and Molecular Imaging, p. 135-153, 2016

Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

Sandström, Mattias; Lindskog, Karolina; Velikyan, Irma; Wennborg, Anders et al.

Part of Journal of Nuclear Medicine, p. 867-871, 2016

• DOI for Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule Ga-68-ABY-025 in Breast Cancer Patients

Non-invasive determination of HER2-expression in metastatic breast cancer by using Ga-68-ABY025 PET/CT.

Lindman, Henrik; Wennborg, Anders; Velikyan, Irina; Feldwisch, Joachim et al.

Part of Journal of Clinical Oncology, 2015

EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

Carlsson, Jörgen; Wester, Kenneth; De La Torre, Manuel; Malmström, Per-Uno et al.

Part of Radiology and Oncology, p. 50-58, 2015

• DOI for EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides

Good manufacturing practice compliant production of a Ga-68-labelled Affibody agent for breast cancer imaging: first-in-human

Velikyan, Irina; Wennborg, Anders; Feldwisch, Joachim; Orlova, Anna et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2015

Measuring HER2-expression in metastatic breast cancer using 68Ga-ABY025 PET/CT

Sörensen, Jens; Velikyan, Irina; Wennborg, A.; Feldwisch, J. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

GMP compliant preparation of a (68)Gallium-labeled Affibody analogue for breast cancer patient examination: first-in-man

Velikyan, Irina; Wennborg, A.; Feldwisch, J.; Orlova, Anna et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

Radiation dosimetry and tracer kinetic analysis of Ga-68-ABY025 Affibody in breast cancer patients

Lubberink, Mark; Lindskog, K.; Sandström, Mattias; Velikyan, Irina et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, 2014

First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Sörensen, Jens; Sandberg, Dan; Sandström, Mattias; Wennborg, Anders et al.

Part of Journal of Nuclear Medicine, p. 730-735, 2014

• DOI for First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule
• Download full text (pdf) of First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the In-111-ABY-025 Affibody Molecule

Imaging ff HER2-Expression in Breast Cancer Metastases (Review)

Carlsson, Jorgen

Part of Anticancer Research, p. 5855-5855, 2014

HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides

Wei, Qichun; Xu, Jing; Shen, Li; Fu, Xianhua et al.

Part of Tumor Biology, p. 6319-6326, 2014

• DOI for HER2 expression in primary gastric cancers and paired synchronous lymph node and liver metastases. A possible road to target HER2 with radionuclides

Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

Carlsson, J.; Shen, L.; Xiang, J.; Xu, J. et al.

Part of Oncology Letters, p. 208-214, 2013

• DOI for Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors

Carlsson, Jörgen

Part of Tumor Biology, p. 653-659, 2012

• DOI for Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors

Effects of affinity on binding of HER2-targeting Affibody molecules: Model experiments in breast cancer spheroids

Qvarnström, O. Fredrik; Simonsson, Martin; Carlsson, Jörgen; Tran, Thuy A.

Part of International Journal of Oncology, p. 353-359, 2011

• DOI for Effects of affinity on binding of HER2-targeting Affibody molecules: Model experiments in breast cancer spheroids

EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Wei, Q.; Shui, Y.; Zheng, S.; Wester, Kenneth et al.

Part of Oncology Reports, p. 3-11, 2011

• DOI for EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Nuclisome: a novel concept for radionuclide therapy using targeting liposomes

Fondell, Amelie; Edwards, Katarina; Ickenstein, Ludger M; Sjöberg, Stefan et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 114-123, 2010

• DOI for Nuclisome: a novel concept for radionuclide therapy using targeting liposomes

Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

Göstring, Lovisa; Chew, Ming Tsuey; Orlova, Anna; Höidén-Guthenberg, Ingmarie et al.

Part of International Journal of Oncology, p. 757-763, 2010

• DOI for Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects

Effects of an EGFR-binding affibody molecule on intracellular signaling pathways

Nordberg, Erika; Ekerljung, Lina; Häggblad Sahlberg, Sara; Carlsson, Jörgen et al.

Part of International Journal of Oncology, p. 967-972, 2010

• DOI for Effects of an EGFR-binding affibody molecule on intracellular signaling pathways

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule

Friedman, Mikaela; Lindstrom, Sara; Ekerljung, Lina; Andersson-Svahn, Helene et al.

Part of Biotechnology and applied biochemistry, p. 121-131, 2009

• DOI for Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule

gamma H2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids

Qvarnström, O. F; Simonsson, M; Eriksson, V; Turesson, I et al.

Part of International Journal of Oncology, p. 41-47, 2009

• DOI for gamma H2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids

Differences in radiosensitivity between three HER2 overexpressing cell lines

Steffen, Ann-Charlott; Göstring, Lovisa; Tolmachev, Vladimir; Palm, Stig et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1179-1191, 2008

• DOI for Differences in radiosensitivity between three HER2 overexpressing cell lines

Cross-fire doses from β-emitting radionuclides in targeted radiotherapy: A theoretical study based on experimentally measured tumor characteristics

Enger, Shirin Abbasinejad; Hartman, Torbjörn; Carlsson, Jörgen; Lundqvist, Hans

Part of Physics in Medicine and Biology, p. 1909-1920, 2008

• DOI for Cross-fire doses from β-emitting radionuclides in targeted radiotherapy: A theoretical study based on experimentally measured tumor characteristics

Targeting EGFR and HER2 with 211At-labeled molecules: unexpected and expected dose-effect relations in cultured tumor cells

Carlsson, Jörgen; Steffen, Ann-Charlott; Sundberg, Åsa L.; Vikström, Mikael et al.

Part of Current radiopharmaceuticals, p. 225-233, 2008

In vivo and in vitro uptake of In-111, delivered with the affibody molecule(Z(EGFR:955))(2), in EGFR expressing tumour cells

Nordberg, Erika; Orlova, Anna; Friedman, M.; Tolmachev, Vladimir et al.

Part of Oncology Reports, p. 853-857, 2008

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

Wei, Qichun; Sheng, Liming; Shui, Yongjie; Hu, Qiongge et al.

Part of Annals of Surgical Oncology, p. 1193-1201, 2008

• DOI for EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line

Ekerljung, Lina; Lindborg, Malin; Gedda, Lars; Frejd, Fredrik Y. et al.

Part of Biochemical and Biophysical Research Communications - BBRC, p. 489-494, 2008

• DOI for Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line

Effects of radiation on growth of two human tumour cell lines surviving a previous high dose, low dose-rate, radionuclide exposure

Segerström, Lova; Stenerlow, Bo; Eriksson, Veronika; Carlsson, Jörgen

Part of International Journal of Oncology, p. 341-9, 2008

• DOI for Effects of radiation on growth of two human tumour cell lines surviving a previous high dose, low dose-rate, radionuclide exposure

Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

Monazzam, Azita; Josephsson, Raymond; Blomqvist, Carl; Carlsson, Jörgen et al.

Part of Breast Cancer Research, 2007

• DOI for Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer

Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Tolmachev, Vladimir; Orlova, Anna; Pehrson, Rikard; Galli, Joakim et al.

Part of Cancer Research, p. 2773-2782, 2007

• DOI for Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule

Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor

Friedman, Mikaela; Nordberg, Erika; Höidén-Guthenberg, Ingmarie; Brismar, Hjalmar et al.

Part of Protein Engineering Design & Selection, p. 189-199, 2007

• DOI for Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor

[Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts

Persson, Mikael; Gedda, Lars; Lundqvist, Hans; Tolmachev, Vladimir et al.

Part of Cancer Research, p. 326-331, 2007

• DOI for [Lu-177]pertuzumab: Experimental therapy of HER-2-expressing xenografts

EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases

Wei, Qichun; Chen, Lirong; Sheng, Liming; Nordgren, Hans et al.

Part of International Journal of Oncology, p. 493-499, 2007

Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule

Nordberg, Erika; Friedman, Mikaela; Göstring, Lovisa; Adams, Gregory et al.

Part of Nuclear Medicine and Biology, p. 609-618, 2007

• DOI for Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule

Biodistribution of 211At labeled HER-2 binding affibody molecules in mice

Steffen, Ann-Charlott; Almqvist, Ylva; Chyan, Ming-Kuan; Lundqvist, Hans et al.

Part of Oncology Reports, p. 1141-1147, 2007

Outcome of percutaneous coronary intervention in hospitals with and without on-site cardiac surgery standby

Carlsson, Jörg; James, Stefan; Ståhle, Elisabeth; Höfer, Sebastian et al.

Part of Heart, p. 335-338, 2007

• DOI for Outcome of percutaneous coronary intervention in hospitals with and without on-site cardiac surgery standby

Penetration of tumor therapy interesting substances in non-vascularized metastases; Review of studies in cellular spheroids

Carlsson, Jörgen; Gedda, Lars

Part of Current Cancer Therapy Reviews, p. 293-304, 2006

Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue

Ekberg, Thomas; Nestor, Marika; Engström, Mats; Nordgren, Hans et al.

Part of International Journal of Oncology, p. 1177-85, 2005

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Persson, Mikael; Tolmachev, Vladimir; Andersson, Karl; Gedda, Lars et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 1457-62, 2005

• DOI for [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells

Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.

Nordberg, Erika; Steffen, Ann-Charlott; Persson, Mikael; Sundberg, Åsa L. et al.

Part of European Journal of Nuclear Medicine and Molecular Imaging, p. 771-7, 2005

• DOI for Cellular uptake of radioiodine delivered by trastuzumab can be modified by the addition of epidermal growth factor.

In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics

Steffen, Ann-Charlott; Wikman, Maria; Tolmachev, Vladimir; Adams, Gregory P. et al.

Part of Cancer Biotherapy and Radiopharmaceuticals, p. 239-248, 2005

Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases

Gårdmark, Truls; Wester, Kenneth; De la Torre, Manuel; Carlsson, Jörgen et al.

Part of BJU International, p. 982-986, 2005

• DOI for Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases

Radionuklidterapi - möjlig väg mot bättre behandling av cancer: Hindret är bristen på kommersiellt tillgängliga nuklider i kliniken

Lundqvist, Hans; Carlsson, Jörgen; Gedda, Lars; Tolmachev, Vladimir et al.

Part of Läkartidningen, p. 1000-1006, 2004

Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice

Tolmachev, Vladimir; Orlova, Anna; Wei, Qichun; Bruskin, Alexander et al.

Part of Cancer Biotherapy and Radiopharmaceuticals, p. 491-501, 2004

• DOI for Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice

[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma

Sundberg, Åsa Liljegren; Gedda, Lars; Orlova, Anna; Bruskin, Alexander et al.

Part of Cancer Biotherapy and Radiopharmaceuticals, p. 195-204, 2004

• DOI for [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma

A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy: availability of suitable radionuclides

Tolmachev, Vladimir; Carlsson, Jörgen; Lundqvist, Hans

Part of Acta Oncologica, p. 264-75, 2004

Targeting against epidermal growth factor receptors: Cellular processing of astatinated EGF after binding to cultured carcinoma cells

Orlova, Anna; Sjöström, Anna; Lebeda, Ondrej; Lundqvist, Hans et al.

Part of Anticancer Research, p. 4035-4042, 2004

Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI)

Bruskin, Alexander; Sivaev, Igor; Persson, Mikael; Lundqvist, Hans et al.

Part of Nuclear Medicine and Biology, p. 205-11, 2004

HER2 expression in breast cancer primary tumours and corresponding metastases: Original data and literature review

Carlsson, Jörgen; Nordgren, Hans; Sjöström, J.; Wester, Kenneth et al.

Part of British Journal of Cancer, p. 2344-2348, 2004

Selection and characterization of HER2/neu-binding affibody ligands

Wikman, Maria; Steffen, Ann-Charlott; Gunneriusson, Elin; Tolmachev, Vladimir et al.

Part of Protein Engineering Design & Selection, p. 455-462, 2004

• DOI for Selection and characterization of HER2/neu-binding affibody ligands

Preparation, radioiodination, and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides

Tolmachev, Vladimir; Bruskin, Alexander; Sjöberg, Stefan; Carlsson, Jörgen et al.

Part of Journal of Radioanalytical and Nuclear Chemistry, p. 107-112, 2004

• DOI for Preparation, radioiodination, and in vitro evaluation of a nido-carborane-dextran conjugate, a potential residualizing label for tumor targeting proteins and peptides

Ligand liposomes and boron neutron capture therapy

Carlsson, Jörgen; Bohl Kullberg, Erika; Capala, Jacek; Sjöberg, Stefan et al.

Part of Journal of Neuro-Oncology, p. 47, 2003

HER-2: A possible target for therapy of metastatic urinary bladder carcinoma

Wester, Kenneth; Sjöström, Anna; de la Torre, Manuel; Carlsson, Jörgen et al.

Part of Acta Oncologica, p. 282-288, 2002

• DOI for HER-2: A possible target for therapy of metastatic urinary bladder carcinoma

Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents

Bohl Kullberg, Erika; Bergstrand, Nill; Carlsson, Jörgen; Edwards, Katarina et al.

Part of Bioconjugate chemistry, p. 737-743, 2002

• DOI for Development of EGF-conjugated liposomes for targeted delivery of boronated DNA-binding agents

Radiation therapy through activation of stable nuclides.

Carlsson, Jörgen; Forssell-Aronsson, Eva; Glimelius, Bengt

Part of Acta Oncol, p. 629-34, 2002

Differences in the growth inhibition of cultured K-562 cells by selenium, mercury or cadmium in two tissue culture media (RPMI-1640, Ham's F-10).

Frisk, Peter; Yaqob, Amer; Nilsson, Kenneth; Carlsson, Jörgen et al.

Part of Biometals, p. 101-11, 2000

Conjugate chemistry and cellular processing of EGF-dextran

Carlsson, Jörgen; Blomquist, Erik; Gedda, Lars; Liljegren, Åsa et al.

Part of Acta Oncologica, p. 313-321, 1999

Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases

Mahteme, Haile; Lövqvist, A; Graf, Wilhelm; Lundqvist, Hans et al.

Part of Anticancer Research, p. 843-848, 1998

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications

Löfblom, John; Feldwisch, Joachim; Tolmachev, Vladimir; Carlsson, Jörgen et al.

Part of FEBS Letters, p. 2670-2680, 2010

• DOI for Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications

Targeting the epidermal growth factor receptor family in radionuclide therapy of tumors-signal transduction and DNA repair

Lennartsson, Johan; Carlsson, Jörgen; Stenerlöw, Bo

Part of Letters in Drug Design & Discovery, p. 357-368, 2006

Targeted Radionuclide Tumor Therapy: Biological Aspects

Carlsson, Jörgen; Stigbrand, Torgny; Adams, Gregory P.

Springer, 2008

Radiation Induced DNA-Damage/Repair and Associated Signaling Pathways

Stenerlöw, Bo; Ekerljung, Lina; Carlsson, Jörgen; Lennartsson, Johan

Part of Targeted Radionuclide Tumor Therapy, p. 249-266, Springer, 2008

Introduction to radionuclide therapy

Carlsson, Jörgen

Part of Targeted Radionuclide Tumor Therapy, p. 1-11, Springer, 2008

EGFR-family expression and implications for targeted radionuclide therapy

Carlsson, Jörgen

Part of Targeted Radionuclide Therapy, p. 25-58, Springer, 2008

Developmental trends in targeted radionuclide therapy: Biological aspects

Carlsson, Jörgen

Part of Targeted Radionuclide Tumor Therapy, p. 387-398, Springer, 2008

Effects of low dose-rate radiation on cellular survival

Carlsson, Jörgen

Part of Targeted Radionuclide Tumor Therapy, p. 295-310, Springer, 2008

Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I

Lebeda, Ondrej; Orlova, Anna; Tolmachev, Vladimir; Lundqvist, Hans et al.

Part of Contemporary Boron Chemistry, Royal Society of Medicine Press, 2000

• DOI for Effect of ionizing radiation on the labeling of closo-dodecaborate(2-) anion with 125I

Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells

Orlova, Anna; Sjöström, Anna; Ericson, A.; Lebeda, Ondrej et al.

Part of Journal of labelled compounds & radiopharmaceuticals, 2001

• DOI for Cellular processing of indirectly astatinated and iodinated mAb A33 in SW1222 cultured cells

Penetration and Binding of EGF-Dextran Conjugates in Cultured-Cell Spheroids

Nilsson, Per; Gedda, Lars; Sjöstrom, Anna; Zhao, Qinghai et al.

Part of European Journal of Cell Biology, p. 118-118, 1997